Latest News

I love writing guest articles and collaborating
See appearances for Asa's events and podcasts 

Aug 5, 2022

Press Mention

Rachel Adams

Compliance responsibilities when using a contract manufacturer

Brands need to ensure regulatory responsibilities are accounted for at the start of a contract manufacturing partnership.

Compliance responsibilities when using a contract manufacturer

Aug 1, 2022

Interview

Mychealla Rice

The Future of CBD research, marketing, and regulation

In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at Supplement Advisory Group, discuss Atlantia’s expertise in clinical trials for CBD

The Future of CBD research, marketing, and regulation

Jul 8, 2022

Interview

Sheldon Baker

Limiting Marketing Risk for Hemp and CBD Products

Asa Waldstein, principal at Supplement Advisory Group, advises companies on how to navigate murky waters in today's marketplace.

Limiting Marketing Risk for Hemp and CBD Products

Jun 1, 2022

Press Mention

Josh Long

NDI warning letters fuel criticism of FDA enforcement approach—again

Former FDA officials and lawyers who advise clients on FDA regulations weigh in on a recent batch of warning letters targeting new dietary ingredients marketed in supplements.

NDI warning letters fuel criticism of FDA enforcement approach—again

May 3, 2022

Guest Article

Asa Waldstein

Compliance Essentials for Hemp-CBD Companies, Part 3 of 3: Marketing

Compliance Essentials for Hemp-CBD Companies, Part 3 of 3: Marketing

May 3, 2022

Guest Article

Asa Waldstein

Q2 FDA warning letter roundup with Asa Waldstein

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Q2 FDA warning letter roundup with Asa Waldstein

May 2, 2022

Press Mention, Data Mention

Isabella Davis

Mental Wellbeing in Today's Digital Age

Presentation

Mental Wellbeing in Today's Digital Age

Apr 19, 2022

Interview

EU’s new THC limits for hemp-based products will ‘level the playing field’ for food producers

Asa and other industry leaders interviewed

EU’s new THC limits for hemp-based products will ‘level the playing field’ for food producers

Apr 4, 2022

Press Mention

Lex Pelger, White Whale Creations

White Whale Creations Newsletter

Asa Waldstein's content is mentioned in this newsletter.

White Whale Creations Newsletter

Apr 1, 2022

Guest Article

Asa Waldstein

Compliance Essentials for Hemp-CBD Companies Part 2 of 3

This edition talks about labeling essentials and best practices.

Compliance Essentials for Hemp-CBD Companies Part 2 of 3

Mar 30, 2022

Relevant Article

Hemp Industry Daily

FDA, FTC slap CBD industry with seven warning letters related to COVID claims

Asa Waldstein quoted

FDA, FTC slap CBD industry with seven warning letters related to COVID claims

Mar 17, 2022

Interview

Danielle Masterson

Stress: What can you claim on a product label?

Asa Waldstein and two top advertising attorneys share their tips and best practices for marketing stress supplements.
🔷Stress-free rules Ivan Wasserman, Amin Talati Wasserman, LLP
🔷Pooja's do's and don'ts Pooja Nair
🔷Asa's helpful hints Supplement Advisory Group

Stress: What can you claim on a product label?

Mar 16, 2022

Press Mention

Julia Peterman

#NaturallyInformed Event Looks at Immune Health from All Angles

Asa Waldstein, Principal, Supplement Advisory Group, discussed the most recent info on FDA and FTC’s thinking regarding immune support in Communicating in-store and online—where are we now? “FDA is going back many years and citing multi-year-old social media posts in warning letters,” he shared. “One cited a social media post from 2014, and they treat those the same way as new posts. Hashtags are also claims. ‘Liking’ a post is a claim. Replying to or reposting a customer comment on social media, that’s a claim. All marketing is considered ‘labeling’.” That includes, he said, product reviews and testimonials; infographics; citing studies; blogs; and more.

#NaturallyInformed Event Looks at Immune Health from All Angles

Mar 1, 2022

Guest Article

Asa Waldstein

Q1 FDA warning letter roundup with Asa Waldstein

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Q1 FDA warning letter roundup with Asa Waldstein

Feb 18, 2022

Guest Article

Asa Waldstein

Compliance Essentials for Hemp-CBD Companies Part 1 of 3

This edition talks about manufacturing essentials and reasons to think twice when building an overly robust Quality Management System (QMS).

Compliance Essentials for Hemp-CBD Companies Part 1 of 3

Jan 28, 2022

Interview

Laura Drotleff

Researchers, hemp leaders caution cannabis producers against profiteering on early COVID research

Asa and other industry leaders interviewed

Researchers, hemp leaders caution cannabis producers against profiteering on early COVID research

Jan 11, 2022

Guest Article

Let's Talk Hemp Media

Hemp Industry 2022 Opportunities Report

Asa writes the FDA and Hemp section of this prestigious annual paid publication.

Hemp Industry 2022 Opportunities Report

Dec 22, 2021

Interview

Jean Lotus

Hemp Leaders Look Ahead to 2022

Asa and other industry leaders interviewed

Hemp Leaders Look Ahead to 2022

Oct 13, 2021

Interview

Kate Robertson

Product Reviews & Marketing Claims

Asa and other industry leaders interviewed

Product Reviews & Marketing Claims

Sep 21, 2021

Interview

Cait Curley and Asa Waldstein

Influencers and CBD: Be Careful What You Say

Asa is interviewed by a well-known influencer on the topic. This is applicable to the dietary supplement industry as well. Read here: https://www.letstalkhemp.com/hemp-influencers/

Influencers and CBD: Be Careful What You Say